CN111728903B - Injection and cosmetic composition containing lemon balm extract as active ingredient - Google Patents
Injection and cosmetic composition containing lemon balm extract as active ingredient Download PDFInfo
- Publication number
- CN111728903B CN111728903B CN202010024143.1A CN202010024143A CN111728903B CN 111728903 B CN111728903 B CN 111728903B CN 202010024143 A CN202010024143 A CN 202010024143A CN 111728903 B CN111728903 B CN 111728903B
- Authority
- CN
- China
- Prior art keywords
- extract
- weight
- lemon balm
- cosmetic composition
- minimally invasive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9711—Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides a cosmetic composition and an injection composition, wherein the cosmetic composition comprises: lemon balm extract having lipolytic effect, purified water, sodium chloride, aesculus hippocastanum seed extract, walnut extract, tyrosine, fucus extract, adenosine phosphate, disodium adenosine triphosphate, methyl propylene glycol, methylsilanol mannuronate, the injection composition comprising: lemon balm extract, aesculus hippocastanum extract, fucus vesiculosus extract, juglandis extract, disodium adenosine phosphate, adenosine triphosphate, and tyrosine.
Description
Technical Field
The present invention relates to an injection and a cosmetic composition containing an extract of lemon balm as an active ingredient.
Background
In general, a long V-line face is the face type that anyone wants. In particular, the trend in recent years is to increase the number of people who want to be away from the fat face and form facial lines with a sharp contour.
A complex formulation injection using Phosphatidylcholine (PPC) and sodium deoxycholate (sodium deoxycholate) has been widely used for local obesity with the purpose of fat reduction (lipoplasty).
However, although a lipolysis composition using a single sodium deoxycholate preparation, in which phosphatidylcholine is removed, has been developed because of the occurrence of fat necrosis due to the injection using the complex preparation of phosphatidylcholine and sodium deoxycholate, there is a problem that side effects such as edema, erythema, pain, and skin induration frequently occur in the case of a lipolysis composition using a single sodium deoxycholate preparation.
In one aspect, cosmeceutical (Cosmeceutical) is used as a synthetic term for cosmetics (cosmectics) and pharmaceuticals (pharmaceuticals) to mean cosmeceuticals. It is a product of a medicinal component whose cosmetic binding effect is verified. Cosmetics which are researched and developed by medical professionals such as doctors, pharmacists and the like also belong to pharmaceutical cosmetics. If the existing cosmetics are for skin management, the cosmeceutical products focus on skin treatment.
There is also a continuously increasing demand for weight loss therapy (sliming) and anti-cellulite (anti-cellulite) cosmetics that are effective in removing excess subcutaneous fat and enhancing skin elasticity.
Disclosure of Invention
Problems to be solved
The present invention has been made to solve the above-mentioned problems of the prior art, and an object of the present invention is to provide an injection composition which can easily make the face slender by injection.
The purpose of the present invention is to provide a cosmetic composition which is applied to the skin, directly decomposes fat in adipocytes, and can exhibit a cellulite removal effect.
Means for solving the problems
According to an embodiment of the present invention, there is provided a composition for lipolysis comprising a lemon balm leaf extract as an active ingredient, which comprises the lemon balm leaf extract, an Aesculus Hippocastanum (Aesculus Hippocastanum) extract, an Fucus Vesiculosus (Fucus Vesiculosus) extract, a walnut (Juglans Regia) extract, disodium Adenosine Phosphate (ADP), adenosine Triphosphate (Adenosine Triphosphate), and Tyrosine (Tyrosine).
According to an embodiment of the present invention, there is provided an injection composition for lipolysis containing the composition as an active ingredient.
According to a first embodiment of the present invention, there is provided an injection composition having an extract of lemon balm as an effective ingredient, comprising: 0.898% by weight of sodium chloride, 0.11462% by weight of propylene glycol, 0.0468% by weight of phenoxyethanol, 0.04% by weight of methylpropanediol, 0.01875% by weight of lemon balm leaf extract, 0.00800% by weight of tyrosine, 0.00560% by weight of aesculus hippocastanum seed extract, 0.00560% by weight of walnut extract, 0.00520% by weight of ethylhexyl glycerol, 0.00240% by weight of fucus extract, 0.00180% by weight of methylsilanol mannuronate, 0.00100% by weight of sorbic acid, 0.00024% by weight of adenosine phosphate, 0.00024% by weight of disodium adenosine triphosphate, and the balance of purified water.
According to a second embodiment of the present invention, there is provided a cosmetic composition having lemon balm extract as an effective ingredient, comprising: purified water, sodium chloride, lemon balm leaf EXTRACT, aesculus hippocastanum seed EXTRACT, juglandis (Juglans regia) EXTRACT, tyrosine (Tyrosine), fucus VESICULOSUS EXTRACT (Fucus VESICULOSUS EXTRACT), adenosine Phosphate (Adenosine Phosphatate), DISODIUM Adenosine TRIPHOSPHATE (disodiose Adenosine TRIPHOSPHATE), methyl propylene glycol (ospyro propylene glycol), METHYLSILANOL MANNURONATE (METHYLSILANOL manonate).
According to a second embodiment of the present invention, there is provided a cosmetic composition containing lemon balm extract as an active ingredient, the cosmetic composition comprising: 0.898% by weight of sodium chloride, 0.01875% by weight of lemon balm extract, 0.00800% by weight of tyrosine, 0.00560% by weight of aesculus hippocastanum seed extract, 0.00560% by weight of walnut extract, 0.00240% by weight of fucus vesiculosus extract, 0.00024% by weight of adenosine phosphate, 0.00024% by weight of disodium adenosine triphosphate, 0.04000% by weight of methyl propylene glycol, 0.00180% by weight of methylsilanol mannuronate and the balance of purified water, and said composition is applied to the skin by ultrasonic equipment, high frequency equipment, electroporation, or needleless syringe.
Effects of the invention
According to the present invention, an injection composition containing the lemon balm extract as an active ingredient, which can easily grow the face by injection alone, can be provided.
According to the present invention, a cosmetic composition for decomposing fat in an application area and removing cellulite using lemon balm extract as an active ingredient can be provided.
Drawings
Fig. 1 is a graph showing clinical results of minimally invasive surgery performed by an injection composition according to an embodiment of the present invention.
Fig. 2 is an enlarged photograph of a tissue showing distribution of adipocytes before the adipocytes are put into the injection composition according to an embodiment of the present invention.
Fig. 3 is a magnified photograph of a tissue showing 80% reduction of adipocytes after administration of an injection composition according to an embodiment of the present invention.
Fig. 4 and 5 show photographs before/after performing a minimally invasive surgery for four weeks using the injection composition according to an embodiment of the present invention.
Fig. 6 and 7 are graphs showing clinical results of minimally invasive surgery using the cosmetic composition according to the embodiment of the present invention.
Fig. 8 and 9 show photographs before and after performing a minimally invasive surgery for four weeks of a cosmetic composition according to an embodiment of the present invention.
Detailed Description
Specific embodiments of the present invention will be described in detail below with reference to the accompanying drawings.
In the composition for lipolysis containing lemon balm extract as an active ingredient according to an embodiment of the present invention, for lipolysis, lymphatic circulation, V-line face, elastic face, it is administered subcutaneously as an injection, or applied as a cosmetic composition.
The composition according to the embodiment of the present invention may be used for minimally invasive surgery on correcting facial lines by lipolysis upon injection into the upper eyelid fat, lower eye fat, cheek flesh, cheekbones, mouth side fat, mandible lines, mandible, etc. The composition is an effective composition that can be finely sculptured according to the state of the face of an individual. Has effects in relieving edema, decomposing fat, promoting lymph circulation, and eliminating cellulite.
The lipolytic composition according to an embodiment of the present invention preferably comprises lemon balm leaf extract, aesculus Hippocastanum (Aesculus hippopastanum) extract, fucus vesiculosus (fucus vesiculosus) extract, walnut (Juglans Regia) extract, disodium Adenosine Phosphate (ADP), adenosine Triphosphate (Adenosine Triphosphate), tyrosine (Tyrosine).
The lipolytic injection composition according to the first embodiment of the present invention preferably consists of the following ingredients.
[ Table 1]
Table 1 is a table showing the components and combination ratios of the injection composition according to the first embodiment of the present invention. The numbers indicate weight%.
Lemon balm (Melissa officinalis) is a plant belonging to the Labiatae family (Labiatae) and is known to contain various active xanthophylls (luteolin (cycloside), cosmosin (cosmosin), rhamnocitrin (rhamnocitrin), isoquercitrin (isoquercitrin)), terpenes and triterpenic acids (triterpenic acids), ursolic acid (urslic acid) and oleanolic acid (oleanolic acid) (Herodez SS, hadolin M, skerget M, knez Solvent extract of antioxidant from anthropogenic acid L) leave Chemistry 200; 80-275 (Solvent extraction research chemical 200 for antioxidant from sesame oil) and also the active components of sesquiterpenes and caffeic acids, and melissic acid, etc. are isolated from fojac acid, melissic acid and melissic acid, and the like. Antibacterial of Lemon balm extract (Ulbricht C, brendler T, gruenwald J, kligler B, keifer D, abrams TR, woods J, boon H, kirkwood CD, hackman DA, basch E, laffert HJ; natural Standard Research leather of Lemon balm L) (Natural Standard Research of Lemon balm L) 2005 hold 71-114, antiviral and antioxidant activity (S, yarahagia S, bonaugh R, bough et L) 2005, bioprotection of the liver of the rat (biological of hyperlipidemia of the biological of Lipemia of the rat); 99, ali Zarei1, saeed Changizi Ashtiyani, soheila Tahei, fate Rasekh company between effects of different drugs of the family of drugs on the activity of lever enzymes in hypercholesterolaemia) AJP 2014;4 (1) 15-23; ). Melissa officinalis leaf extract is Melissa officinalis leaf extract, is a medicinal herb which grows in the coastal and middle regions of the Mediterranean sea and is called "Melissa", and is characterized by having a fragrance similar to that of lemon and containing a rich rosmarinic acid component. The rosmarinic acid has weight reducing, antioxidant, and antiinflammatory effects. The lemon balm leaf extract is a polyphenol and tannin component, and also has excellent effect on skin protection. The lemon balm extract is a substance obtained by extracting the whole plant of lemon balm, preferably the leaves of lemon balm, with a polar solvent selected from the group consisting of water, methanol, ethanol and a mixture of two or more thereof, preferably with water, and then spray-drying the extract to obtain a powder.
The extract of Aesculus HIPPOCASTANUM (Horse chestnum) SEED extract not only has anti-edema, anti-inflammatory, anti-edema, and anti-catarrhal effects, but also has effects of protecting skin from ultraviolet rays, preventing generation of black spots, and preventing rough skin.
The WALNUT EXTRACT (Juglans REGIA (WALNUT) SEED EXTRACT) has not only the effects of promoting the differentiation of horny layer from keratinocyte in cells and recovering the wall function of injured skin, but also has remarkable effects of increasing and maintaining moisturizing ability, and also has remarkable effects of preventing degranulation in adipocyte and proliferating immunocyte, and has anti-inflammatory and irritation relieving effects.
Fucus VESICULOSUS EXTRACT (Fucus VESICULOSUS EXTRACT) is a component extracted from large brown algae, contains various minerals, vitamins, amino acids, and thus protects the skin and absorbs water, and has the effect of moisturizing and drying the skin. And, it helps absorb fat and discharge excrement.
SODIUM CHLORIDE (SODIUM CHLORIDE) is an inorganic salt component that is a compound of SODIUM and CHLORIDE and is used as an acidity regulator, preservative function, fragrance, viscosity improver in cosmetics and cosmetic products.
PROPYLENE GLYCOL (PROPYLENE GLYCOL) is a component obtained by hydrolyzing PROPYLENE oxide, and is used for the purpose of permeating an active ingredient because it has a small molecular weight and is excellent in skin permeation force. Has effects in maintaining moisture in skin and improving skin moisture retention.
PHENOXYETHANOL (PHENOXYETHANOL) is a component combining phenol and ethylene glycol, is mainly used as a preservative and an antistaling agent in cosmetics, and is one of the preservatives used in cosmetics instead of parabens which are famous once for breast cancer.
Methyl propylene glycol (METHYLPROPANEDIOL) is one of ethylene glycols used as a solvent. It helps various components (salicylic acid, etc.) penetrate into skin. Has water absorption (Hydrating) property, and helps to soften and moisturize skin.
TYROSINE (TYROSINE) is a skin amino acid that begins to produce melanin. It can be used as precursor of Catecholamine (cathecholamine) and Thyroxine (Thyroxine, which is thyroid hormone) in vivo for promoting fat metabolism.
Ethylhexyl glycerin (ETHYLHEXYLGLYCERIN) is a glycerin ether, which is an organic compound ingredient, and is one of a kind of glycerin, which is a softening, humectant and a humectant having a proper spreading function. The antibacterial power of preservatives such as phenoxyethanol, isothiazolinone and paraben is increased, and the amount of the preservatives used can be reduced. Inhibiting bacterial growth to provide a deodorizing effect and skin conditioning.
METHYLSILANOL MANNURONATE (METHYLSILANOL MANNURONATE) is a substance that binds Silanol (Silanol) of organosilicon (SI) and Mannuronic Acid (Mannuronic Acid) of alginic Acid derived from brown algae, and has skin regeneration, elasticity enhancement, stretch mark prevention effects, anti-oxidation, lipolysis, moisturizing effects, and the like.
SORBIC ACID (SORBIC ACID) is a component present in berries such as blueberry, and has a growth inhibitory effect on microorganisms such as bacteria and mold, and is therefore mainly used as a preservative component for all cosmetics. It is not only in cosmetics, but also in food-acceptable ingredients.
ADENOSINE PHOSPHATE (ADENOSINE PHOSPHATE) is a complex wrinkle improving, anti-inflammatory, calming, cell-communicating ingredient (cell-communicating ingredients), delivers skin cells in the dermis to activate oxygen, and enhances the size increase and proliferation of fibroblasts to promote collagen synthesis.
DISODIUM ADENOSINE TRIPHOSPHATE (DISODIUM ADENOSINE TRIPHOSPHATE) is the DISODIUM salt component of ADENOSINE TRIPHOSPHATE. Is used to provide conditioning to the skin.
The subjects to be treated include a case where the face looks strong due to the development of cheekbones, a case where the chin lines of cheeks drop with the aging, a case where the chin wrinkles look deep due to both cheeks near the chin wrinkles, a case where the region of the chin or the both chin is fatty, a case where the four corners and the chin cannot be corrected only by botulinum toxin, a case where the face lines cannot be corrected even by contour or bimaxillary surgery, a case where there is fear of fat inhalation or surgery, a case where fat transplantation is excessive, before and after lifting, a case where the face is asymmetric, a case where the effect is not obtained by a conventional lipolysis drug, and a case where the daily life is not affected in a short time and the face is desired to be modified.
The clinical results of the injection administration are as follows.
The patient age will be for male and female patients over 20 years old. Results after 4 minimally invasive surgeries were performed once a week for one month. The minimally invasive surgery is performed for 30 to 40 minutes after ointment anesthesia, and a 32G needle (1 cc syringe) (32G needle (1 cc system)) and a Meissner gun (Mesogun) are used. For the infusion (Solution) of the composition containing lemon balm extract as an active ingredient, it is injected subcutaneously (SQ level) at 3-4 points per 1 cc. Gently massaging after minimally invasive surgery, and applying antibiotic ointment or Vit.
Table 2 below is a table showing the number of minimally invasive operations, the amount and the interval according to the site of minimally invasive operations.
[ Table 2]
The patient with the minimally invasive surgery shows more than 80-90% of the effect. In the overall pattern, the cheeks' down (jowl fat) and mandible lines show the most strikingly varying pattern, the effect of which does appear from 2-3 weeks. After the use of the drug, there is no edema or burning sensation and no sense of inconvenience in carrying out daily life. In the case of patients who need to perform a wire drawing operation and a botulinum toxin minimally invasive surgery, the satisfaction degree as a concurrent minimally invasive surgery is higher. In particular, the contour drugs also participate in lymphatic metabolism, thereby showing excellent effects on edema relief and cellulite decomposition. That is, as shown in fig. 1, 19% indicates a decrease in hard cellulite, 32% indicates a decrease in edema cellulite, and 49% indicates a soft cellulite reduction effect.
Fig. 2 and 3 show electron micrographs illustrating an experiment in which a composition according to an embodiment of the present invention reacts to adipocytes. FIG. 2 is a photograph before the composition is put in, and FIG. 3 is a photograph after the composition is put in. The red circle (fig. 2 and 3 are submitted in the form of black and white color charts so as to comply with the regulations of the chinese patent law, if it is required to confirm the red circle, refer to fig. 2 and 3 of the drawings of the korean priority specification of the present application) represents fat cells, and it can be confirmed that fat cells are reduced by about 80%.
Fig. 4 and 5 show photographs before and after performing a minimally invasive surgery four weeks using an injection composition according to an embodiment of the present invention, respectively. As shown in the figure, a noticeable change in facial lines was confirmed at week 4 due to decomposition of fat and cellulite.
On the other hand, the following describes a lemon balm extract cosmetic composition according to a second embodiment of the present invention, which contains lemon balm extract as an active ingredient.
The cosmetic composition for lipolysis containing the lemon balm extract according to the embodiment of the present invention as an effective ingredient may be applied from the cosmetic composition for lipolysis, lymphatic circulation, V-line face, and elastic face.
The lipolytic composition according to an embodiment of the present invention preferably comprises lemon balm leaf extract, aesculus Hippocastanum (Aesculus Hippocastnum) extract, fucus Vesiculosus (Fucus Vesiculosus) extract, juglans Regia (Juglans Regia) extract, ADP (Disodium Adenosine Phosphonate), adenosine Triphosphate (Adenosine Triphosphate), tyrosine (Tyrosine).
The cosmetic composition for decomposition of fat according to the second embodiment of the present invention is preferably composed of the following components.
[ Table 3]
Table 3 is a table showing components and combination ratios of the cosmetic composition for lipolysis according to the second example of the present invention. The numbers show the% by weight.
The description of the same components as in example 1 is omitted.
The lemon balm extract is obtained by extracting the whole plant of lemon balm, preferably the leaf of lemon balm, with a polar solvent selected from the group consisting of water, methanol, ethanol and a mixture of two or more thereof, preferably water, and then spray-drying the extract to obtain a powder. In this example, the effect of reducing fat and cellulite when lemon balm extract is applied to the skin is utilized.
From 1 month to 3 months in 2019, 100 minimally invasive surgery patients were clinically treated with the composition as subjects.
As shown in table 4 below, minimally invasive surgery patients were classified into cellulite categories of minimally invasive surgery patients.
[ Table 4]
Soft cellulite (soft cellulite) | 49% |
Hard fat mass (hard cellulose) | 19% |
Cellulite (edematous cellulite) | 32% |
* The age of the 70 minimally invasive surgery patients was as follows. 70% of minimally invasive surgical patients are 15-35 years old.
[ Table 5]
15-25 years old | 40% |
26-35 years old | 30% |
Age 36-45 | 18% |
Age 46-55 | 10% |
56-65 years old | 2% |
Circulatory system diseases are particularly important, however, the symptoms associated with cellulite are very diverse as in table 6 below.
[ Table 6]
As shown in Table 6, 65% of minimally invasive surgical patients were shown to have inadequate venous return (deficiency venous return), 44% to have family history varicose abnormalities (family history of variant vessels), and 31% to have ankle edema (maloler edema) at least two days prior to physiology. All these symptoms are statistically proven to be very well associated with blood vessels (vascular interventions). Therefore, it is associated with poor circulatory function (or circulatory function) and cosmetic cellulite problems (abnormal cell formulas).
Electroporation (electroporation) was applied to all of the corresponding sites of minimally invasive surgery including around the trochanter portion (peritrochanteric) and the inner side of the knee, and the following results were obtained. Electroporation, which means electroporation, is a method in which skin lipids are opened up in a timed manner by applying an electric pulse to the skin lipids, and thus, formulation absorption of a composition such as according to an embodiment of the present invention is more effective.
The clinic is performed 1 time per week over 4-10 weeks, depending on the status of the minimally invasive surgery patient. Thereafter, the treatment was performed a total of two times every other week 1 time, and was performed only once a month for "maintenance purpose" after performing the treatment twice. The power level is 75-90% from a minimum of 30 minutes to a maximum of 40 minutes per time. It should be noted that the massage is performed just as if it were lightly circled at the applicable site. In addition to the minimally invasive surgery of "maintenance purpose", the minimally invasive surgery patients who received the minimally invasive surgery of 5 to 10 times in total are 71%, the minimally invasive surgery patients who received the minimally invasive surgery of 11 to 20 times including "maintenance purpose" are 25%, and the minimally invasive surgery patients who received the minimally invasive surgery of 21 times or more are 4%.
The changes in body weight loss are shown in Table 7 below.
[ Table 7]
0~3kg | 26% |
3~6kg | 40% |
6~9kg | 22% |
9~12kg | 9% |
12~15kg | 1% |
Fig. 6 is a graph of the reduction of diameter around the rotor (peritrochonteric) (fig. 6 of the present invention can be referred to in korean priority text of the present invention if it is disclosed as a black and white photograph). 21% shows a reduction effect of 2cm, 46% shows a reduction effect of 3cm, and 21% shows a reduction effect of 4cm (fig. 6 is submitted in the form of a black and white color chart so as to comply with the regulations of the chinese patent laws, please refer to fig. 6 of the accompanying drawings of the korean priority specification of the present application if needed for clearer content).
Fig. 7 is a table showing comprehensive evaluations of minimally invasive surgical patients. Subjective evaluation of minimally invasive surgery patients in minimally invasive surgery is formed, and evaluation criteria include not only changes in body weight but also the degree of syndrome (side effect) which may occur during minimally invasive surgery, rapid return to daily life, and the like.
General vasodilation in both thighs was observed in 3% of minimally invasive surgery patients. This is temporary and without pain, not a symptom caused by the vagus nerve (vagal). It is a phenomenon that the lower thigh portion disappears after becoming hazily red, and is understood as the degree of response to the homeopathic product.
It is worth noting that the patients who participate in clinical minimally invasive surgery have no drug resistance and no rejection reaction to the same therapy. The acceptance (acceptance) of the product by minimally invasive surgery patients is very excellent, and the itching, swelling, allergic phenomena, pain, severe erythema and the like are completely avoided.
Fig. 8 is a photograph of a 29 year old female before (a) and after (b) minimally invasive surgery. Results were obtained after 1 minimally invasive surgery for 6 weeks.
Fig. 9 is a photograph of a 43-year-old female before (a) and after (b) minimally invasive surgery. Results were obtained by performing minimally invasive surgery 1 time a week for 10 weeks.
As shown, a dramatic change in the fat deposition site was confirmed by the decomposition of fat and cellulite at the minimally invasive surgery site.
Claims (2)
1. An injection composition containing lemon balm extract as an active ingredient, comprising: 0.898% by weight of sodium chloride, 0.11462% by weight of propylene glycol, 0.0468% by weight of phenoxyethanol, 0.04% by weight of methylpropanediol, 0.01875% by weight of lemon balm leaf extract, 0.00800% by weight of tyrosine, 0.00560% by weight of aesculus hippocastanum seed extract, 0.00560% by weight of walnut extract, 0.00520% by weight of ethylhexyl glycerol, 0.00240% by weight of fucus extract, 0.00180% by weight of methylsilanol mannuronate, 0.00100% by weight of sorbic acid, 0.00024% by weight of adenosine phosphate, 0.00024% by weight of disodium adenosine triphosphate, and the balance purified water.
2. A cosmetic composition containing lemon balm extract as an active ingredient, the cosmetic composition comprising: 0.898 wt% of sodium chloride, 0.01875 wt% of lemon balm extract, 0.00800 wt% of tyrosine, 0.00560 wt% of aesculus hippocastanum seed extract, 0.00560 wt% of walnut extract, 0.00240 wt% of fucus extract, 0.00024 wt% of adenosine phosphate, 0.00024 wt% of disodium adenosine triphosphate, 0.04000 wt% of methyl propylene glycol, 0.00180 wt% of methylsilanol mannuronate and the balance of purified water,
the composition is applied to the skin by an ultrasonic device, a high frequency device, electroporation, or a needleless injector.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190033690A KR102036186B1 (en) | 2019-03-25 | 2019-03-25 | Composition comprising lemon balm extract for lipolysis |
KR10-2019-0033690 | 2019-03-25 | ||
KR10-2019-0050030 | 2019-04-29 | ||
KR1020190050030A KR102027827B1 (en) | 2019-04-29 | 2019-04-29 | Composition comprising lemon balm extract for lipolysis |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111728903A CN111728903A (en) | 2020-10-02 |
CN111728903B true CN111728903B (en) | 2022-11-01 |
Family
ID=72611582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010024143.1A Active CN111728903B (en) | 2019-03-25 | 2020-01-10 | Injection and cosmetic composition containing lemon balm extract as active ingredient |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP6943941B2 (en) |
CN (1) | CN111728903B (en) |
WO (1) | WO2020197041A1 (en) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007091645A (en) * | 2005-09-29 | 2007-04-12 | Ichimaru Pharcos Co Ltd | Food/drink for antiobese use containing melia azadirachta l. extract |
CN101277710A (en) * | 2005-10-05 | 2008-10-01 | 血管实验室公司 | Antiobesity composition |
WO2012033422A1 (en) * | 2010-09-06 | 2012-03-15 | Aleksandar Pavlov | Medical cosmetic herbal composition on the basis of herbal mixture and the procedure for its obtention |
KR20120086436A (en) * | 2011-01-26 | 2012-08-03 | 주식회사 코스메카코리아 | Cosmetic composition for slimming |
CN103687586A (en) * | 2012-01-23 | 2014-03-26 | 雷斯托尔西有限公司 | Cosmetic |
CN107149582A (en) * | 2017-05-13 | 2017-09-12 | 佛山文森特知识产权服务有限公司 | A kind of anti-apolexis composition and its application |
CN108125892A (en) * | 2017-12-11 | 2018-06-08 | 百朗德生物化学(海门)有限公司 | A kind of marine organism moisture-retention anti-aging cosmetics composition |
CN108309834A (en) * | 2018-04-19 | 2018-07-24 | 广州赛莱拉干细胞科技股份有限公司 | Skin care compositions based on brown alga extract |
CN109316431A (en) * | 2017-07-31 | 2019-02-12 | 株式会社忻秀韩国 | Composition for chest enlarge and improvement skin elasticity |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5081203B2 (en) * | 2003-07-29 | 2012-11-28 | 花王株式会社 | Lipolysis accelerator |
JP2008074814A (en) * | 2006-09-25 | 2008-04-03 | Nivea Kao Kk | Lipolysis promoter |
CN109464452A (en) * | 2018-12-28 | 2019-03-15 | 广州涵夏基因健康科技有限公司 | Application of the adenosine triphosphate salt in preparation external application fat-eliminating slimming product |
KR102027827B1 (en) * | 2019-04-29 | 2019-10-02 | 임재선 | Composition comprising lemon balm extract for lipolysis |
KR102036186B1 (en) * | 2019-03-25 | 2019-10-24 | 임재선 | Composition comprising lemon balm extract for lipolysis |
-
2019
- 2019-12-04 WO PCT/KR2019/017047 patent/WO2020197041A1/en active Application Filing
- 2019-12-25 JP JP2019234300A patent/JP6943941B2/en active Active
-
2020
- 2020-01-10 CN CN202010024143.1A patent/CN111728903B/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007091645A (en) * | 2005-09-29 | 2007-04-12 | Ichimaru Pharcos Co Ltd | Food/drink for antiobese use containing melia azadirachta l. extract |
CN101277710A (en) * | 2005-10-05 | 2008-10-01 | 血管实验室公司 | Antiobesity composition |
WO2012033422A1 (en) * | 2010-09-06 | 2012-03-15 | Aleksandar Pavlov | Medical cosmetic herbal composition on the basis of herbal mixture and the procedure for its obtention |
KR20120086436A (en) * | 2011-01-26 | 2012-08-03 | 주식회사 코스메카코리아 | Cosmetic composition for slimming |
CN103687586A (en) * | 2012-01-23 | 2014-03-26 | 雷斯托尔西有限公司 | Cosmetic |
CN107149582A (en) * | 2017-05-13 | 2017-09-12 | 佛山文森特知识产权服务有限公司 | A kind of anti-apolexis composition and its application |
CN109316431A (en) * | 2017-07-31 | 2019-02-12 | 株式会社忻秀韩国 | Composition for chest enlarge and improvement skin elasticity |
CN108125892A (en) * | 2017-12-11 | 2018-06-08 | 百朗德生物化学(海门)有限公司 | A kind of marine organism moisture-retention anti-aging cosmetics composition |
CN108309834A (en) * | 2018-04-19 | 2018-07-24 | 广州赛莱拉干细胞科技股份有限公司 | Skin care compositions based on brown alga extract |
Also Published As
Publication number | Publication date |
---|---|
JP2020158484A (en) | 2020-10-01 |
CN111728903A (en) | 2020-10-02 |
JP6943941B2 (en) | 2021-10-06 |
WO2020197041A1 (en) | 2020-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105395406B (en) | The anti-aging Essence of nourishing and the anti-aging cosmetics of nourishing based on Chinese herbal medicine | |
CN108653129B (en) | Skin dressing containing natural plant anti-allergy composition | |
KR102027827B1 (en) | Composition comprising lemon balm extract for lipolysis | |
US7205009B2 (en) | Composition for treating hair and scalp and method for preparing same | |
CN111973481A (en) | Blue ketone peptide repair essence and preparation method thereof | |
US20070031367A1 (en) | Composition and method for neck skin firming | |
US20190216871A1 (en) | Diabetic foot cream | |
KR102330465B1 (en) | Composition for skin comprising pine bark extract reducing edema, cellulite, breaking down body fat, promoting blood circulation and skin cream comprising thereof | |
US20060045894A1 (en) | Compound for neck skin firming | |
CN105250606A (en) | Natural plant acne removing agent | |
CN111728903B (en) | Injection and cosmetic composition containing lemon balm extract as active ingredient | |
CN107441340B (en) | Hand and foot chap cream for relieving swelling, pain and itching and nourishing skin and preparation method thereof | |
KR102036186B1 (en) | Composition comprising lemon balm extract for lipolysis | |
US20160106798A1 (en) | Topical treatment for use in conjunction with acupuncture or acupressure therapy | |
EP0841895A1 (en) | Slimming cream based on plants | |
EP3706714B1 (en) | N-acetylcysteine and urea-based formulation for the treatment of dermatological disorders | |
AU2018359924B2 (en) | Composition for eliminating striae distensae | |
US9421235B2 (en) | Medicine containing extracts of Ficus microcarpa for healing wounds of a diabetic patient | |
CA2620242A1 (en) | Topical soothing bruise healing preparation | |
RU2369377C1 (en) | Phytobalsam insofit for skin regeneration | |
CN110812377A (en) | Acne treatment and repair composition and application thereof | |
CN110269830A (en) | A kind of Bletilla glucomannan repair latex and its preparation and application | |
CN115844784B (en) | Composition for relieving inflammation of dry skin and application and preparation method thereof | |
KR102576331B1 (en) | Injection composition for local fat removal and operating method thereof | |
CN115671239B (en) | Anti-inflammatory, detumescence, antibacterial, antipruritic, anticracking and repairing jelly-curing cream and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |